TET2 and chronic myelogenous leukemia, BCR-ABL1 positive: TET3 shares significant sequence homology with TET1 and TET2. Sequencing analysis of TET3 in myeloid malignancy, excluding CML, revealed no mutations among 96 myeloproliferative neoplasm patients.27 However, because TET2 and TET3 have overlapping requirements in hematopoietic stem cell emergence, the TET3 mutation may play a role in CML.28